It is a global biopharmaceutical company that focuses on the following segments: respiratory, inflammation and autoimmunity, cardiovascular and metabolic diseases, oncology, infection, neuroscience, and gastrointestinal disorders.
- Five Key Clinical Profiles
gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus Active ulceration of the upper gastrointestinal tract Angina pectoris that requires the use of anti-anginal medication Ventricular arrhythmias except for benign premature ven
MEDTRONIC' S NEUROMODULATION DIVISION INCLUDES IMPLANTABLE NEUROSTIMULATION AS WELL AS TARGETED DRUG DELIVERY SYSTEMS (WITH THE COMBINED PRODUCTS TERMED " NEUROMODULATION" ) FOR THE MANAGEMENT OF CHRONIC PAIN, GASTROINTESTINAL DISORDERS, MOVEMENT DISORDERS, SPASTICITY AND UROLOG
Auris Medical Holding AG (EARS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Auris Medical Holding AG (Auris Medical) is a pharmaceutical company that develops pharmaceutical therapies to protect hearing and to silence tinnitus.
Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 188.8.131.52) - Pipeline Review, H2 2017
- Number of Products under Development by Indication, H2 2017
Rice University is investigating WBZ-## for the treatment of gastrointestinal stromal tumor.
(NYSE: GI), which offers physicians a broad portfolio of products to treat gastrointestinal conditions, for approximately $## million.
- OTITIS MEDIA - PIPELINE BY OTONOMY INC, H1 2017
- OTITIS MEDIA - PIPELINE BY LEE'S PHARMACEUTICAL HOLDINGS LTD, H1 2017
The company offers over-the-counter products for pain relief, oral health, nutrition, skin health and gastrointestinal disorders.
- OTITIS MEDIA - PIPELINE BY MERLION PHARMACEUTICALS PTE LTD, H2 2017
- OTITIS MEDIA - PIPELINE BY MERCK & CO INC, H2 2017
MerLion Pharma' s product is used for the treatment of urinary tract, respiratory tract, skin and soft tissue, intra-abdominal and gastrointestinal infections.
- OTONOMY ENTERS INTO LICENSING AGREEMENT WITH IPSEN
- Otonomy Inc, Pharmaceuticals & Healthcare, Deal Details
The company' s portfolio of therapies focus at treating neuroendocrine tumors, prostate, bladder and kidney cancer, pituitary diseases, growth disorders precocious puberty, spasticity, cervical dystonia, hemifacial spasm, blepharospasm, gastrointestinal disorders, neurodegenerative path
NOV ##, 2014: ENTEROMEDICS TO PARTICIPATE AT THE 2014 CANACCORD GENUITY MEDICAL TECHNOLOGY AND DIAGNOSTICS FORUM EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, announced that Greg